JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A3969 Vatalanib
1 Citation

Target: VEGFR

Summary: VEGFR-1/-2 inhibitor,cell-permeable

≥16.85 mg/mL
A8236 Regorafenib
4 Citation

Target: Raf|VEGFR|PDGFR|c-Kit|RET

Summary: Inhibitor of VEGFR/PDGFR/FGFR/mutant kit/RET/Raf-1

≥25.04 mg/mL
A8252 Nintedanib (BIBF 1120)
3 Citation

Target: VEGFR|PDGFR|FGFR

Summary: VEGFR/PDGFR/FGFR inhibitor

insoluble in H2O; insoluble in EtOH; ≥5.34 mg/mL
A2949 Linifanib (ABT-869)

Target: VEGFR|PDGFR

Summary: VEGFR/PDGFR inhibitor

insoluble in H2O; insoluble in EtOH; ≥18.75 mg/mL
A1882 Cediranib (AZD217)

Target: VEGFR

Summary: VEGFR inhibitor receptor,highly potent

≥22.52 mg/mL
A2597 Brivanib (BMS-540215)

Target: VEGFR|FGFR|Flk1

Summary: VEGFR-2 inhibitor,ATP-competitive

insoluble in H2O; ≥18.5 mg/mL
A5057 MGCD-265

Target: VEGFR|c-MET

Summary: Met/Flt/Flk/Ron/Tie-2 inhibitor

≥25.9 mg/mL
A1778 Vatalanib (PTK787) 2HCl

Target: VEGFR

Summary: Tyrosine kinase receptor inhibitor

≥21 mg/mL
A8313 RAF265

Target: Raf|VEGFR

Summary: Multiple intracellular kinases inhibitor

≥25.9 mg/mL
A8550 Telatinib (BAY 57-9352)

Target: VEGFR|PDGFR|c-Kit

Summary: VEGFR-2/-3,PDGFR-β and c-Kit inhibitor

insoluble in H2O; insoluble in EtOH; ≥20.5 mg/mL